ERCC2 and metastatic neoplasm: For example, the ERCC2 mutation frequency in a cohort of MIBC patients treated with cisplatin-based NAC is likely to be higher than in the subset of these same patients who ultimately develop metastatic disease, since ERCC2-mutant patients are more likely to have a complete response — and thus less likely to develop metastatic disease — than patients lacking a tumor ERCC2 mutation.